Navigation Links
KemPharm, Inc. Announces Plans to Launch KP106 as First Oral Film Dosage Form for ADHD
Date:4/25/2011

y," commented Travis Mickle, Ph.D., President and Chief Executive Officer, KemPharm.

"This collaboration is a natural strategic fit for MonoSol Rx and our PharmFilm® technology," commented A. Mark Schobel, President and Chief Executive Officer, MonoSol Rx.  "KemPharm is a true pharmaceutical innovator, and through the combination of KP106 and PharmFilm®, there is the potential to introduce a novel ADHD product that could represent a safer, more convenient treatment option for ADHD patients.  We look forward to working together to maximize the commercial potential of KP106 through this partnership."

About KP106

KP106, KemPharm's lead prodrug candidate for the treatment of ADHD, is composed of d-amphetamine and a ligand.  In clinical studies, KP106 demonstrated pharmacokinetics indicative of an attenuated amphetamine exposure as compared to Vyvanse®.  These data suggest that patients receiving KP106 may experience decreased side effects and decreased risk of abuse typically associated with stimulants.  In addition, KemPharm is positioning KP106 to be the first ever proprietary oral film dosage form for ADHD.  KemPharm projects the filing of a new drug application (NDA) for KP106 in 1H2013.

About KemPharm, Inc.

KemPharm, Inc. is focused on the discovery and development of new chemical entities (NCEs) to treat serious medical conditions through its proprietary and broadly applicable LAT prodrug approach.  KemPharm utilizes its LAT prodrug technology to generate improved versions of FDA-approved drugs.  The Company's business strategy includes seeking strategic development partners following rapid clinical proof of concept demonstration in a Phase 1 trial.  KemPharm also plans to explore discovery stage alliances with industry leaders, leveraging its prodrug know-how and LAT technology.  KemPharm is developing candidates for ADHD, pain, other central
'/>"/>

SOURCE KemPharm, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. KemPharm, Inc. Receives Notice of Issuance from USPTO on Second Patent Protecting Companys ADHD Prodrug Technology
2. KemPharm, Inc. Receives Notice of Issuance From USPTO on Patent Protecting Companys ADHD Prodrug Technology
3. PDI Announces Group DCAs Launch of eDetailing Across Apple® and Android™ Mobile Devices
4. Sanofi Pasteur Announces FDA Approval of Menactra Meningococcal Conjugate Vaccine Indication for Infants
5. iMD Companies, Inc. Announces Expansion of OMI Operations
6. Jazz Pharmaceuticals Announces First Quarter 2011 Results Conference Call on May 3
7. Important Drug Product Notice: Luitpold Pharmaceuticals, Inc. Announces Temporary Suspension of Distribution and Manufacture of Drug Products
8. Misonix Announces New Distribution Agreement for Colombia
9. Onyx Pharmaceuticals Announces First Quarter 2011 Financial Results Teleconference and Webcast
10. Marinus Pharmaceuticals Announces Commencement of Phase 2 Trial of Ganaxolone for the Treatment of Posttraumatic Stress Disorder
11. China Botanic Pharmaceutical Announces Plans to Switch to Renewable Bio-Fuel - Straw Pellets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... YORK , Aug. 28, 2014 ... is available in its catalogue: Germany ... 2020 http://www.reportlinker.com/p02343442/Germany-Aesthetic-Lasers-and-Energy-Devices-Market-Outlook-to-2020.html ... Outlook to 2020 Summary GlobalData,s new ... Outlook to 2020", provides key market data on ...
(Date:8/28/2014)... /PRNewswire-iReach/ -- EDGE Orthopaedics, a new entry in ... announce they have received their second FDA 510(k) ... Fracture Plating System. The VIEW Plating ... indications within the mid-foot. The system includes titanium ... (CC), Talonavicular (TN) and Evans plates along with ...
(Date:8/28/2014)... CITY , Aug. 28, 2014 /PRNewswire-iReach/ -- Academy ... by service academy graduates, has published a case ... three-day Leadership Excellence Course . In September and ... Excellence Course to Albuquerque , Indianapolis ... . Photo - http://photos.prnewswire.com/prnh/20140828/140814 ...
Breaking Medicine Technology:Germany Aesthetic Lasers and Energy Devices Market Outlook to 2020 2Germany Aesthetic Lasers and Energy Devices Market Outlook to 2020 3Germany Aesthetic Lasers and Energy Devices Market Outlook to 2020 4Germany Aesthetic Lasers and Energy Devices Market Outlook to 2020 5Germany Aesthetic Lasers and Energy Devices Market Outlook to 2020 6Germany Aesthetic Lasers and Energy Devices Market Outlook to 2020 7Germany Aesthetic Lasers and Energy Devices Market Outlook to 2020 8Germany Aesthetic Lasers and Energy Devices Market Outlook to 2020 9EDGE Orthopaedics Receives Second FDA Clearance 2Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 2Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 3Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 4Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 5
... Cancer Journal , AUSTIN, Texas--(BUSINESS WIRE)--May 30, 2007--Introgen,Therapeutics, ... the dramatic clinical benefit of its lead product,Advexin ... of cancer known as,Li-Fraumeni Syndrome (LFS), a genetic ... suppressor gene. This is the,first reported treatment of ...
... CITY, Calif.--(BUSINESS WIRE)--May 29, 2007 - Gilead,Sciences, ... III,AIR-CF1 (CP-AI-007) study of aztreonam lysine for ... fibrosis (CF) who have,pulmonary Pseudomonas aeruginosa (P. ... at Day 28 from baseline in respiratory,symptoms, ...
Cached Medicine Technology:Introgen's Advexin Demonstrates Clinical Benefit in Inherited,Cancer 2Introgen's Advexin Demonstrates Clinical Benefit in Inherited,Cancer 3Introgen's Advexin Demonstrates Clinical Benefit in Inherited,Cancer 4Gilead Announces Achievement of Primary Efficacy Endpoint in Second,Phase III Study of Aztreonam Lysine for Inhalation in Patients With,Cystic Fibrosis 2Gilead Announces Achievement of Primary Efficacy Endpoint in Second,Phase III Study of Aztreonam Lysine for Inhalation in Patients With,Cystic Fibrosis 3Gilead Announces Achievement of Primary Efficacy Endpoint in Second,Phase III Study of Aztreonam Lysine for Inhalation in Patients With,Cystic Fibrosis 4Gilead Announces Achievement of Primary Efficacy Endpoint in Second,Phase III Study of Aztreonam Lysine for Inhalation in Patients With,Cystic Fibrosis 5
(Date:8/29/2014)... neuroregenerative effect, stimulating neurite extension in the ... and enhancing nerve regeneration following nerve crush ... FK506 to stimulate nerve regeneration is limited ... and hypertension, and its considerable cost. With ... other drugs reportedly cause life-threatening infections. Like ...
(Date:8/29/2014)... August 29, 2014 The Fresh Diet, ... introduce its new Fresh Vegetarian meal plan. Originating from ... meals, the new menu is designed to satisfy customers ... lifestyle. , Responding to the growing demand ... a multi-billion dollar market (Forbes) with 14% of Americans ...
(Date:8/29/2014)... 2014 Glendale Botox experts at ... Botox throughout the month of September. This special offer features ... syringes of Juvederm. Patients can take advantage of this special ... Glendale Botox experts will work with patients to determine if ... What is Botox? , Botox is a treatment made ...
(Date:8/29/2014)... FRIDAY, Aug. 29, 2014 (HealthDay News) -- Researchers have ... in their brains. Dyslexia -- the most commonly ... problems with reading and writing. Previous research showed ... but most of those studies focused only on a ... used functional MRI to analyze how multiple brain regions ...
(Date:8/29/2014)... VA (PRWEB) August 29, 2014 For ... Research Foundation (Meso Foundation) will be observing September 26th ... on Rockefeller Plaza, in New York. , Members ... encouraged to RSVP . The Foundation will be providing ... the past years, mesothelioma community members have received attention ...
Breaking Medicine News(10 mins):Health News:The Fresh Diet America's #1 At-Home Meal Delivery Company, Debuts Fresh Vegetarian Meal Plan Offering All-Natural Ingredients 2Health News:The Fresh Diet America's #1 At-Home Meal Delivery Company, Debuts Fresh Vegetarian Meal Plan Offering All-Natural Ingredients 3Health News:Glenoaks Laser Center is Now Offering a Special Promotion on Botox for the Month of September 2Health News:Scientists Find Differences in Brains of Those With Dyslexia 2Health News:Organization to Raise Awareness of Mesothelioma on the Today Show 2
... A night of food and festivities for a great ... ActionAIDS has shown their appreciation for people who through ... a very real difference in the lives of men, ... recognizes those individuals with their highest honor: The ...
... structuring physician payment incentives around existing empirical evidence ... reduce the cost of healthcare, says a commentary ... Circulation: Cardiovascular Quality and Outcomes . ... suffering from mild chest pain due to coronary ...
... 20 Young Innovations, Inc. (Nasdaq: YDNT ) today ... a live and on-demand web cast conference call on Tuesday, April ... broadcast of the call will be available through InterCall at ... live audio broadcast will also be available through the Company,s website, ...
... Eli Lilly and Company (NYSE: LLY ) today ... $0.49 a share on outstanding common stock. This is ... and maintains the annual indicated dividend rate for 2009 of ... shareholders of record at the close of business on May ...
... (Nasdaq: AMGN ) today announced that it plans ... 23, 2009 after the close of the financial markets. The ... investment community at 2 p.m. Pacific Time. Participating in ... chief executive officer, and other members of Amgen,s senior management ...
... 8-ounce glass enhances absorption of rapamycin 3 to 4 times ... boosts the anti-cancer effects of the drug rapamycin, according to ... tumors, for which there is no effective treatment. , ... as a liquid, once a week. After the first week ...
Cached Medicine News:Health News:Subaru of America CMO Tim Mahoney and Restaurateur Stephen Starr to receive ActionAIDS' Friend for Life Award April 30 2Health News:Subaru of America CMO Tim Mahoney and Restaurateur Stephen Starr to receive ActionAIDS' Friend for Life Award April 30 3Health News:Subaru of America CMO Tim Mahoney and Restaurateur Stephen Starr to receive ActionAIDS' Friend for Life Award April 30 4Health News:Health-care reform should start with paying evidence-based financial incentives to doctors 2Health News:Young Innovations, Inc. Provides First Quarter Conference Call Details 2Health News:Amgen Announces Webcast of 2009 First Quarter Financial Results 2Health News:Grapefruit Juice Boosts Anti-Cancer Drug's Effects 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: